What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2026-02-26 compared with 2025-02-27 · 21 added, 40 removed, 57 unchanged (52% of the section changed)

LEGAL PROCEEDINGS

In June 2023, a putative class action lawsuit was filed against the Company, its Executive Chairman and its former Chief Executive Officer.

The complaint, later amended to add our former Chief Financial Officer as a defendant, purports to be brought on behalf of a class of persons and/or entities who purchased or otherwise acquired ordinary shares of the Company from January 5, 2023 through June 5, 2023, and alleges material misstatements and/or omissions in the Company’s public statements with respect to the results from its Phase 3 LUNAR clinical trial.

The Company believes that the action is without merit and plans to defend the lawsuit vigorously.

In addition, from time to time, we are involved in various legal proceedings, claims, investigations and litigation that arise in the ordinary course of our business.

From time to time, we are involved in various legal proceedings, claims, investigations and litigation that arise in the ordinary course of our business.

Litigation is inherently uncertain.

6 unchanged sentences

Name Age Position

Ashley Cordova

46 Chief Executive Officer

William Doyle 63 Executive Chairman and Director

Frank Leonard

46 Chief Executive Officer

Barak Ben-Arye 50 General Counsel

1 unchanged sentence

52 Chief Financial Officer

Francis Leonard 45 Executive Vice President, President Novocure Oncology

Nicolas Leupin

51 Chief Medical Officer

Mukund Paravasthu

1 unchanged sentence

56 Chief Human Resources Officer

Uri Weinberg 47 Chief Innovation Officer

Ashley Cordova has been our Chief Executive Officer since January 1, 2025.

From September 2020 to December 2024, Ms.

Cordova served as our Chief Financial Officer and from October 2018 to August 2020, she served as our Senior Vice President, Finance and Investor Relations.

Cordova joined us in June 2014 as Director of Global Treasury.

In March 2015, she became our Senior Director, Investor Relations and Global Treasury, and in July 2016, she became our Vice President, Finance and Investor Relations.

Prior to joining us, Ms.

Cordova served in various financial roles at Zoetis Inc.

from 2012 to 2014 and Pfizer Inc.

from 2005 to 2012.

Cordova graduated with a bachelor’s degree in Music and Business from Furman University, and earned her International Master of Business Administration from the University of South Carolina.

Uri Weinberg 48 Chief Medical Officer and Chief Innovation Officer

William Doyle has served as our Executive Chairman since 2016, as Chairman of the Board since 2009 and as a member of our Board of Directors since 2004.

1 unchanged sentence

Prior to 2002, Mr.

Doyle was a member of Johnson & Johnson’s Medical Devices and Diagnostics Group Operating Committee and was Vice President, Licensing and

Acquisitions.

Doyle was a member of Johnson & Johnson’s Medical Devices and Diagnostics Group Operating Committee and was Vice President, Licensing and Acquisitions.

While at Johnson & Johnson, Mr.

12 unchanged sentences

Doyle serves on Harvard Business School’s Board of Dean’s Advisors and MIT’s Institute of Medical Engineering & Science Visiting Committee.

Frank Leonard was appointed Novocure’s Chief Executive Officer (CEO) in November 2025.

Before his appointment as CEO, Mr.

Leonard was named the company’s President in June 2025.

He was responsible for Novocure’s global business operations, which he led since January 2024, and was responsible for sales, marketing, field medical

affairs, patient experience, public affairs, market access, and product and portfolio strategy functions.

Leonard previously led our US business beginning October 2022.

Leonard served as Chief Development Officer from September 2020 to September 2022, and was responsible for engineering, product development, business development and the overall strategic and operational leadership of Novocure’s innovation platforms.

He joined Novocure in 2010 to prepare the company for a commercial launch and held various roles establishing Novocure’s finance, reimbursement, and business development functions.

Prior to joining Novocure, Mr.

Leonard was a venture capital investor focused on high-impact medical technology companies, including Novocure.

He has served as a director of the Medical Device Manufacturers Association (MDMA) since 2023.

Leonard holds an A.B.

from Harvard University and an M.A.

from the London School of Economics and Political Science.

Barak Ben-Arye has been our General Counsel since April 2022 and prior to that was our Vice President, EMEA Counsel since June 2019 and our Senior Director, EMEA Counsel since joining us in 2018.

8 unchanged sentences

Brackmann earned his Master of Business Administration from the SDA Bocconi School of Management, Milan in 2003 and holds a bachelors degree in Business and Economics from the University of Mannheim.

Frank Leonard has been our Executive Vice President, President Novocure Oncology since January 2024.

Leonard joined Novocure in 2010, and most recently served as President, CNS Cancers U.S.

Prior to joining Novocure, Mr.

Leonard was a venture capital investor focused on high-impact medical technologies.

Leonard holds an A.B.

from Harvard and an M.A.

from the London School of Economics and Political Science.

Nicolas Leupin, M.D., Ph.D., has served as our Chief Medical Officer since January 2024.

Leupin previously served as Chief Medical Officer of Molecular Partners AG since August 2019.

Prior to that Dr.

Leupin served as Chief Medical Officer of argenx from 2016.

Leupin holds an M.D.

from the University of Bern, an M.B.A.

from Jones International University and a Ph.D.

from the Université Bourgogne-Franche-Comté.

Mukund Paravasthu has been our Chief Operating Officer since October 2024.

10 unchanged sentences

He earned his bachelor’s degree in economics from the University of Nantes and his master’s degree in strategic marketing from the Grenoble Business School.

Uri Weinberg, M.D., Ph.D.

, has served as our Chief Innovation Officer since January 2023, where he is responsible for expanding the innovative potential of Tumor Treating Fields therapy.

Since joining Novocure in 2008, he has held several positions throughout his tenure with the Company and most recently held the position of Chief Science Officer since 2020.

Uri Weinberg, M.D., Ph.D.,has served as our Chief Innovation Officer since January 2023, leading our scientific and pre-clinical teams, and in February 2026 was also appointed to serve as our Chief Medical Officer and lead our clinical, safety, medical strategy, and biostatistics teams.

Since joining Novocure in 2008, he has held several positions throughout his tenure with the Company and most recently held the position of Chief Science Officer from 2020.

Weinberg holds an M.D.

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings